AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Tonix Pharmaceuticals stock drops despite FDA approval of fibromyalgia treatment.
ByAinvest
Monday, Aug 18, 2025 11:53 am ET1min read
Tonix Pharmaceuticals' stock dropped by about 20% on Monday despite receiving US FDA approval for its fibromyalgia treatment, Tonmya. The stock had surged 19% in after-hours trading on August 15. Trading in the stock was halted.
Tonix Pharmaceuticals' stock experienced a significant drop of about 20% on Monday, despite receiving U.S. Food and Drug Administration (FDA) approval for its fibromyalgia treatment, Tonmya. The stock had surged by 19% in after-hours trading on August 15, following the FDA's approval announcement.The FDA approval of Tonmya, a non-opioid, once-daily bedtime analgesic with a sublingual formulation, marks a significant milestone for the company. Tonmya is the first new FDA-approved therapy for fibromyalgia in over 15 years, targeting a market expected to reach $3.86 billion by 2031 [2].
The approval was based on two Phase 3 clinical trials involving nearly 1,000 patients, which demonstrated that Tonmya significantly reduced daily pain scores compared to placebo at 14 weeks. The drug was generally well tolerated, with common adverse events including oral hypoesthesia, oral discomfort, abnormal product taste, and somnolence [1].
Tonix Pharmaceuticals expects commercial availability of Tonmya to begin in the fourth quarter of 2025. The company plans to host a webcast and conference call on Monday to discuss the approval further [1].
The stock's decline on Monday may be attributed to various factors, including market expectations, potential generic competition, and reimbursement challenges. Despite the FDA approval, investors are cautious about the drug's ability to capture a significant market share and the company's execution of its commercial strategy.
Tonmya's unique sublingual formulation and clinical trial results position it as a potential game-changer in the fibromyalgia treatment landscape, but the stock's performance suggests that investors are closely monitoring the drug's commercial potential and the broader market dynamics.
References:
[1] https://www.investing.com/news/stock-market-news/tonix-pharmaceuticals-stock-halted-ahead-of-fda-approval-news-93CH-4196002
[2] https://www.ainvest.com/news/tonix-pharmaceuticals-fda-approval-tonmya-strategic-implications-market-capture-fibromyalgia-2508/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet